Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.

Ann Endocrinol (Paris)

Department of endocrinology and reference center for rare pituitary diseases, hôpital Timone, assistance publique hôpitaux de Marseille, Aix-Marseille université, 13284 Marseille, France.

Published: June 2012

We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal. Initial presentation was pituitary apoplexy leading to surgery. Dopamine agonists and radiotherapy allowed control of prolactin secretion and pituitary remnant. Metastasis appeared 10 years after initial presentation, leading to the diagnosis of pituitary carcinoma. At that time, dopamine agonists were no more effective; temozolomide, an oral alkylating agent, was administered for 24 cycles, and allowed decrease of the volume of the pituitary lesion and metastases. The patient is still currently followed in our department, 3 years after temozolomide withdrawal: prolactin level and pituitary tumor volume remain controlled without any chemotherapy. To our knowledge, this is the first case of MEN1 prolactin secreting pituitary carcinoma controlled long-term after temozolomide discontinuation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2012.03.001DOI Listing

Publication Analysis

Top Keywords

pituitary carcinoma
16
men1 prolactin
8
prolactin secreting
8
pituitary
8
secreting pituitary
8
carcinoma controlled
8
controlled long-term
8
long-term temozolomide
8
temozolomide withdrawal
8
initial presentation
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!